Latest news about Ganga Pharmaceuticals
Ganga Pharmaceuticals
12.00
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M0.00%
6M+1.69%
1Y-17.81%
5Y+100.00%
More news about Ganga Pharmaceuticals
10Mar 26
Ganga Pharmaceuticals Limited Re-appoints Managing Director for Three-Year Term
Ganga Pharmaceuticals Limited's board has approved the re-appointment of Mr. Bharat Brijmohan Sharma as Managing Director for another three-year term effective April 01, 2026. The decision, made during a board meeting on March 10, 2026, was based on recommendations from the Nomination and Remuneration Committee and Audit Committee, with proper regulatory filings made pursuant to SEBI Listing Regulations.
07Nov 25
Ganga Pharmaceuticals Reports Decline in Revenue and Profit for H1 FY2026
Ganga Pharmaceuticals Limited, an Ayurvedic products company, released unaudited financial results for H1 FY2026 ending September 30, 2025. Revenue from operations decreased by 48.19% to Rs. 136.65 lakhs, while net profit fell by 68.61% to Rs. 2.48 lakhs compared to H1 FY2025. The company converted 10,75,000 warrants into equity shares, raising Rs. 112.88 lakhs and increasing paid-up equity share capital to Rs. 591.15 lakhs. Total assets rose to Rs. 1,016.21 lakhs, and shareholders' funds increased to Rs. 828.50 lakhs as of September 30, 2025.
19Sept 25
Plutus Capital Management Acquires 7.75% Stake in Ganga Pharmaceuticals Through Warrant Conversion
Plutus Capital Management LLP has acquired a 7.75% stake in Ganga Pharmaceuticals Ltd through the conversion of convertible warrants into 375,000 equity shares. The transaction increased Ganga Pharmaceuticals' total equity share capital from Rs. 4.84 crore to Rs. 5.91 crore, with the number of equity shares rising from 48.37 lakh to 59.12 lakh. Plutus Capital now holds 6.34% of the diluted share capital. The acquisition was made through preferential allotment and reported in compliance with SEBI regulations.
05Aug 25
Plutus Capital Management Acquires 7.75% Stake in Ganga Pharmaceuticals Through Warrant Conversion
Plutus Capital Management LLP has acquired a 7.75% stake in Ganga Pharmaceuticals through warrant conversion. The non-promoter entity acquired 3,75,000 shares via preferential allotment on July 17, 2025. This acquisition increased Ganga Pharmaceuticals' equity share capital from Rs. 4,83,65,000 to Rs. 5,91,15,000. Plutus Capital made the necessary disclosures under SEBI regulations on July 31, 2025.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,780.10
(-0.47%)
6,596.50
(+0.30%)
4,339.90
(-0.65%)
1,398.70
(+1.71%)
1,084.60
(+0.74%)
1,267.50
(+0.33%)
2,249.80
(-0.50%)
2,353.00
(-0.70%)
1,463.60
(+1.61%)
1,427.20
(+2.36%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
